Serebrolizin Siropstandartlashtirilgan fermentativ gidroliz jarayoni yordamida cho'chqa miya to'qimalaridan olingan neyropeptid kompleksidir. Uning faol moddalari 80% past molekulyar og'irlikdagi peptidlardan iborat (molekulyar og'irlik).<10kDa) and 20% free amino acids. This combination simulates the functions of natural neurotrophic factors such as BDNF and NGF, which have neuroprotective, neurotrophic, and promoting neural repair effects. Due to the significant influence of temperature, pH value, and light on the stability of peptide substances, their formulation design should avoid high-temperature sterilization or strong acid and alkali environments to prevent peptide chain breakage or amino acid degradation. Low molecular weight peptides require specific dosage forms (such as injections, enteric coated capsules) to achieve blood-brain barrier penetration. The raw materials from pig brain tissue need to be thoroughly removed of proteins, lipids, and endotoxins to reduce immunogenicity. This substance is also a liquid preparation containing high concentrations of sucrose or other sweeteners, commonly used to mask the bitterness of drugs or improve the medication experience for children/elderly people.
Bizning mahsulotlarimiz
|
|
|
|
|
Serebrolizin COA
Cerebrolysin Siropning hujayraga xos bo'lgan so'rilishi va yukning chiqarilishi
Peptid preparatlari kichik molekulyar og'irligi va moslashuvchan tuzilishi tufayli qon{0}}miya to'sig'iga (BBB) kirib borish va maqsadli yetkazib berishda o'ziga xos afzalliklarga ega. Biroq, ularning zaif barqarorligi va fermentativ gidrolizga moyilligi og'iz formulalarining rivojlanishini cheklaydi. Cho'chqa miyasi proteaza gidrolizi natijasida tayyorlangan peptid aralashmasi sifatida serebrolizin past molekulyar og'irlikdagi peptid segmentini o'z ichiga oladi (<10kDa) with a structure similar to endogenous neurotrophic factors such as BDNF and NGF. It can bind to neuronal Trk receptors through the BBB, activate Ras MAPK and PI3K Akt signaling pathways, promote synapse formation and neurotransmitter synthesis. However, currently the main dosage form of Cerebrolysin is injection, and the cellular uptake and release mechanism of the oral syrup dosage form (Serebrolizin Sirop) hali aniq emas.
Hujayraga xos qabul qilishning molekulyar asoslari: retseptorlar{0}}vositalangan maqsadli tanib olish
Trk retseptorlari oilasining o'ziga xos bog'lanishi
Cerebrolysinning asosiy komponenti BDNF ga juda homolog bo'lgan peptid segmentlarini o'z ichiga oladi, ular endogen neyrotrofik omillar funktsiyasini taqlid qilishi va neyronlar yuzasida TrkB retseptorlari bilan bog'lanish orqali signal uzatishni boshlashi mumkin. Tajribalar shuni ko'rsatdiki, Cerebrolizinning periferik in'ektsiyasi mikrogliyaning M2 turiga (yallig'lanishga qarshi fenotip) aylanishiga olib kelishi va IL-6 sekretsiyasini kamaytirishi mumkin, bu TrkB retseptorlari vositachiligida PI3K Akt yo'lining faollashishiga bog'liq. Hujayralarni qabul qilish darajasida TrkB retseptorlari klatrin vositachiligida endotsitoz orqali serebrolizin peptid segmentlarini erta endosomalarga o'z ichiga oladi, so'ngra kech endosomalarga tashish uchun Rab5/Rab7 konvertatsiyasi va oxir-oqibat sitoplazmaga chiqariladi.
Past zichlikdagi lipoprotein retseptorlarining (LRP)-sinergik ta'siri
Trk retseptorlari bilan bir qatorda, Serebrolizindagi ma'lum peptid segmentlari LRP oilasi (masalan, LRP1, LRP2) orqali membranalar bo'ylab tashilishi mumkin. LRP1 BBB endotelial hujayralari va neyronlarida yuqori darajada ifodalangan bo'lib, apolipoprotein E (ApoE) bilan o'zgartirilgan nanozarrachalarni tanib olish va retseptor{4}} vositachiligidagi endositoz orqali dori yetkazib berishni rag'batlantirishga qodir. Potentsial mexanizmdaSerebrolizin Sirop, agar uning peptid segmenti ApoE bilan strukturaviy oʻxshashlikka ega boʻlsa, u LRP1 orqali qon-miya toʻsigʻi va neyronlarning maqsadli oʻzlashtirilishiga erishishi mumkin. Misol uchun, Altsgeymer kasalligi modelida LRP1 vositachiligida A klirensi va neyrotrofik omillarni etkazib berish o'rtasida sinergik ta'sir mavjud bo'lib, Serebrolizin shunga o'xshash mexanizm orqali miya tarqalishini optimallashtirishi mumkinligini ko'rsatadi.
Hujayralarni qabul qilishning kontsentratsiyaga bog'liqligi
Cell uptake experiments showed that the uptake efficiency of Cerebrolysin significantly increased with increasing drug concentration, but there was a saturation threshold. In the high concentration group (>50 mk g/ml), hujayraning so'rilishining ortishi tekislash tendentsiyasiga ega, bu retseptorlarning to'yinganligi yoki endotsitik yo'llarning ortiqcha yuklanishi bilan bog'liq bo'lishi mumkin. Bundan tashqari, qabul qilish samaradorligi hujayra turiga ta'sir qiladi: neyronga o'xshash hujayralar (masalan, SH-SY5Y) neyron bo'lmagan hujayralarga (masalan, HeLa) qaraganda ancha yuqori o'zlashtiriladi va bu ularning retseptorlari vositachiligi-o'ziga xosligini qo'llab-quvvatlaydi.
Transmembran transport mexanizmi: endositozdan ajralib chiqishgacha dinamik tartibga solish
Klatrin vositachiligidagi endositoz (CME)
CME serebrolizin hujayralari tomonidan qabul qilishning asosiy yo'lidir. TrkB retseptorlari ligand bilan bog'langandan so'ng, u adaptiv protein AP-2 orqali klatrinni qabul qilib, dori bilan qoplangan pufakchalarni hosil qiladi. Tajribalar shuni ko'rsatdiki, CME ni inhibe qilish (masalan, xlorpromazinni qo'llash) Serebrolizinning hujayrali so'rilishini sezilarli darajada kamaytirishi mumkin, kaveolin vositachiligidagi endositozni (CavME) inhibe qilish esa CME ning dominant rolini yanada tasdiqlovchi muhim ta'sirga ega emas. Endositozdan so'ng, vesikulalar erta endosomalar bilan birlashadi va Rab5 GTPase orqali membrana sintezini va yuklarni saralashni tartibga soladi.
Hujayra ichidagi qochish va sitoplazmatik bo'shatish
Ichki qochish Cerebrolysin samaradorligining asosiy bosqichidir. Past molekulyar og'irlikdagi peptid segmentlari "proton shimgich effekti" orqali endosoma membranasini buzishi mumkin: endosoma kislotasi (pH)<6) triggers peptide protonation, leading to the influx of chloride ions and water molecules, ultimately causing swelling and rupture of the endosome. In addition, certain peptide segments rich in hydrophobic amino acids may be directly inserted into the endosomal membrane, forming pores to promote release. The Cerebrolysin peptide segment released into the cytoplasm can freely diffuse to the perineum and interact with downstream signaling molecules of TrkB receptors (such as Shc and PLC γ), activating neuroprotective pathways.
Oʻzaro qon-miya toʻsigʻi transport modeli
Qon{0}}miya to'sig'i modelida serebrolizinning transport samaradorligiga okludin va klaudin-5 kabi qattiq birikma oqsillarining ifodalanishi ta'sir qiladi. Tajribalar shuni ko'rsatdiki, Cerebrolysin BBB endotelial hujayralarining qattiq birikmalarini barqarorlashtirishi va rtPA trombolitik terapiyasi natijasida kelib chiqqan endotelial o'tkazuvchanlikning oshishini kamaytirishi mumkin. Ushbu mexanizmga quyidagi yo'llar bilan erishish mumkin:
Matritsa metalloproteinazasi (MMP) faolligini inhibe qilish: Serebrolizin MMP-9 ifodasini pasaytiradi, hujayradan tashqari matritsa degradatsiyasini kamaytiradi va shu bilan BBB yaxlitligini saqlaydi.
Qattiq birikma oqsil sintezini rag'batlantirish: PI3K Akt yo'lini faollashtirish orqali okludin va ZO-1 transkripsiya darajasini ko'taring va hujayralararo ulanishlar kuchini oshiring.
Endotelial hujayra metabolizmini tartibga solish: glyukoza iste'molini va oksidlovchi fosforlanishni oshirish, energiya ta'minotini yaxshilash va BBB funktsiyasini qo'llab-quvvatlash.
Yuklarni chiqarish dinamikasi: vaqt dozasiga bog'liq effektlar
Serebrolizinning yuk chiqarilishi tez dastlabki chiqarilishning ikki fazali xususiyatini ko'rsatadi (<2 hours) and sustained sustained release (2-24 hours). The initial release originates from the free peptide segments adsorbed on the cell membrane surface, while the sustained release stage relies on the gradual release of endocytic vesicles. In the SH-SY5Y cell model, after treatment with 50 μ g/mL Cerebrolysin, the intracellular peptide concentration reached its peak within 1 hour (Cmax ≈ 12 μ M), and then decreased at a rate of half-life (t1/2) ≈ 6 hours, suggesting that it can reduce the frequency of administration by prolonging the action time.
High doses of Cerebrolysin (>100 mk g/ml) retseptorlarning desensitizatsiyasiga olib kelishi mumkin: TrkB retseptorlarining doimiy faollashuvi - arrestinni jalb qilishga, parchalanish uchun retseptorlarning lizosomalarga ichkilashishiga olib keladi va shu bilan hujayra yuzasi retseptorlari zichligini kamaytiradi. Bu mexanizm klinik tadkikotlarda ham isbotlangan: kuniga 30 ml serebrolizinni (taxminan 6,45 g peptid segmentini o'z ichiga olgan) tomir ichiga yuborish yaxshi tolerantlikka ega, ammo dozani 50 ml ga oshirish samaradorlikni sezilarli darajada yaxshilamadi va buning o'rniga ovqat hazm qilish buzilishi kabi salbiy reaktsiyalar xavfini oshirishi mumkin.
Hujayradan tashqari pH, ion kuchi va ferment faolligi Serebrolizinning chiqarilish samaradorligiga sezilarli ta'sir qiladi. Yallig'lanish mikro muhitida (masalan, IBS bilan og'rigan bemorlarning ichaklarida) mahalliy pH ning pasayishi (<6.5) and an increase in protease activity (such as trypsin and chymotrypsin) may accelerate peptide degradation and reduce bioavailability. To optimize delivery efficiency, future formulation development needs to consider:
PH sezgir tashuvchisi: Serebrolizinni inkapsulatsiyalash va uni ishqoriy ichak muhitida barqaror ravishda chiqarish uchun poli (sut kislotasi glikolik kislotasi) kopolimer (PLGA) nanozarrachalaridan foydalanish.
Ferment inhibitörleri kombinatsiyasi: oshqozon-ichak buzilishini kamaytirish uchun metoklopramid kabi proteaz inhibitörleri bilan birgalikda ishlatiladi.
Maqsadli modifikatsiya: polietilen glikol (PEG) funksionalizatsiyasi orqali aylanma vaqtini uzaytirish yoki so'rilishini kuchaytirish uchun ichakning o'ziga xos ligandlari (masalan, B12 vitamini) bilan bog'lash.
Klinik qo'llash istiqbollari va muammolari
Ovqat hazm qilish affektiv o'qi bilan bog'liq kasalliklarda potentsial
Serebrolizin bilvosita ovqat hazm qilish affektiv o'qini quyidagi yo'llar orqali boshqarishi mumkin:
Ichak mikrobiota neyrotransmitter o'qini yaxshilash: BDNF ifodasini tartibga solish orqali SCFA ning neyrogenezga sinergik ta'sirini kuchaytirish, FGIDli bemorlarda visseral yuqori sezuvchanlikni yumshatish.
Neyroyallig'lanishni inhibe qilish: LPS tufayli mikrogliya faollashuvini kamaytirish, IL-6 kabi yallig'lanishga olib keladigan omillar darajasini pasaytirish va IBS-D bilan og'rigan bemorlarda diareya belgilarini yaxshilash.
Vagus nerv signallarini optimallashtirish: PFC amigdala pastadir funktsiyasini kuchaytirish, vagus nerv signallarining hissiy talqinini yaxshilash va funktsional qorin og'rig'ini engillashtirish.
Doza shaklini optimallashtirishdagi asosiy masalalar
Cerebrolysin Siropning hozirgi tadqiqotlari va ishlanmalari quyidagi muammolarni hal qilishi kerak:
Barqarorlik: Peptidlar oshqozon-ichak traktida fermentativ gidrolizlanish xavfini tug'diradi va barqarorlikni oshirish uchun nanokapsulyatsiya yoki kimyoviy modifikatsiyani talab qiladi.
Bioakkumulyatsiya: og'iz orqali so'rilishning past darajasi, kuchliroq kirish qobiliyatiga ega bo'lgan tashuvchi tizimlarni ishlab chiqishni talab qiladi (masalan, hujayra penetratsion peptid modifikatsiyasi).
Xavfsizlik: Uzoq muddatli foydalanish antikor ishlab chiqarishni qo'zg'atishi mumkin va IgE darajalari va allergik reaktsiyalarni kuzatib borish kerak.
Issiq teglar: serebrolizin sirop, etkazib beruvchilar, ishlab chiqaruvchilar, zavod, ulgurji, sotib olish, narx, ommaviy, sotish